Repligen Analyst Price Targets - Benzinga

Repligen Corp

RGENNASDAQ

Trade with Public

Trade with Public

$178.34

2.921.66%

最終更新: Oct 14, 2:31 PM

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

© 2026 Benzinga | All Rights Reserved

Repligen Analyst Price Targets - Benzinga

Repligen Analyst Price Targets

Wall Street analyst price targets and consensus rating for Repligen (RGEN).

Price Target Range — 13 Quarters

Analyst Consensus — 18 Analysts

15Buy

3Hold

Consensus RatingBuy# Analysts18Avg. Consensus PT$177Upside to Avg. PT-0.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$175→$225
Sep 9, 2026	UBS	Dan Leonard	PT Raise	Buy	$195→$225
Jul 30, 2026	Wells Fargo	Evan Stampler	PT Raise	Overweight	$180→$185
Jul 29, 2026	JP Morgan	Casey Woodring	PT Raise	Overweight	$165→$175
Jul 7, 2026	Benchmark	Robert Wasserman	Upgrade	Hold→Buy	$185
Jul 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Raise	Outperform	$150→$160
Jun 3, 2026	HSBC	Sidharth Sahoo	PT Cut	Buy	$170→$150
Jun 2, 2026	Wolfe Research	Mike Polark	Assumes	Outperform	$145
May 15, 2026	RBC Capital	Dan Leonard	Reinstates	Outperform	$160
May 6, 2026	JP Morgan	Casey Woodring	PT Cut	Overweight	$180→$165
May 6, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$145→$160
Apr 20, 2026	Canaccord Genuity	Kyle Mikson	PT Cut	Hold	$165→$145
Apr 17, 2026	Roth Capital	Natalya Davies	Initiate	Buy	$160
Apr 14, 2026	Barclays	Luke Sergott	PT Cut	Overweight	$175→$145
Apr 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Cut	Outperform	$170→$140
Mar 23, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$180→$208
Feb 25, 2026	UBS	Dan Leonard	PT Cut	Buy	$200→$195
Feb 25, 2026	Barclays	Luke Sergott	PT Cut	Overweight	$200→$175
Feb 25, 2026	Wells Fargo	Brandon Couillard	PT Cut	Overweight	$190→$180
Feb 25, 2026	Evercore ISI Group	Daniel Markowitz	PT Cut	Outperform	$180→$170

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on Repligen, Raises Price Target to $225

Barclays analyst Luke Sergott maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $175 to $225.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Repligen, Raises Price Target to $225

UBS analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Buy and raises the price target from $195 to $225.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Repligen, Raises Price Target to $185

Wells Fargo analyst Evan Stampler maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $180 to $185.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Repligen, Raises Price Target to $175

JP Morgan analyst Casey Woodring maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $165 to $175.

Benzinga Newsdesk

Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition

Repligen to acquire BioLife Solutions for $1.5B to boost cell therapy bioprocessing capabilities and expand global reach.

Vandana Singh

PRO
Benchmark Upgrades Repligen to Buy, Announces $185 Price Target

Benchmark analyst Robert Wasserman upgrades Repligen (NASDAQ:RGEN) from Hold to Buy and announces $185 price target.

Benzinga Newsdesk